In this study, we aim to encapsulate PCA within BSA-NPs and conjugate these nanoparticles with folic acid to target lung cancer cells through dual mechanisms: folate receptor-mediated endocytosis and albumin binding. Here, FLVCR1 is linked to lung cancer.